About Lipase member H
Lipase member H (LIPH) is a protein
from Homo sapiens identified by UniProt accession
Q8WWY8, 451 residues long.
MolForge cross-references it against 0 known binders and
198 disease associations.
Target properties
| Protein name | Lipase member H |
|---|
| UniProt accession | Q8WWY8 |
|---|
| Gene | LIPH |
|---|
| Organism | Homo sapiens |
|---|
| Length | 451 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (198)
Diseases linked to this target (Open Targets).
- woolly hair, autosomal recessive 2, with or without hypotrichosis · score 0.69
- hypotrichosis simplex · score 0.68
- Woolly hair · score 0.38
- type 2 diabetes mellitus · score 0.37
- sex hormone-binding globulin measurement · score 0.25
- genetic disorder · score 0.19
- peak expiratory flow · score 0.13
- lung adenocarcinoma · score 0.11
- cutaneous melanoma · score 0.11
- esophageal cancer · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8WWY8-F1 | alphafold | PREDICTED | 90.99 | — |
Amino-acid sequence (451 residues)
MLRFYLFISL LCLSRSDAEE TCPSFTRLSF HSAVVGTGLN VRLMLYTRKN LTCAQTINSS AFGNLNVTKK TTFIVHGFRP TGSPPVWMDD LVKGLLSVED MNVVVVDWNR GATTLIYTHA SSKTRKVAMV LKEFIDQMLA EGASLDDIYM IGVSLGAHIS GFVGEMYDGW LGRITGLDPA GPLFNGKPHQ DRLDPSDAQF VDVIHSDTDA LGYKEPLGNI DFYPNGGLDQ PGCPKTILGG FQYFKCDHQR SVYLYLSSLR ESCTITAYPC DSYQDYRNGK CVSCGTSQKE SCPLLGYYAD NWKDHLRGKD PPMTKAFFDT AEESPFCMYH YFVDIITWNK NVRRGDITIK LRDKAGNTTE SKINHEPTTF QKYHQVSLLA RFNQDLDKVA AISLMFSTGS LIGPRYKLRI LRMKLRSLAH PERPQLCRYD LVLMENVETV FQPILCPELQ L
Explore Lipase member H with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets